William Richard White Sells 139,083 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO William Richard White sold 139,083 shares of the firm’s stock in a transaction dated Wednesday, July 24th. The shares were sold at an average price of $26.98, for a total value of $3,752,459.34. Following the transaction, the chief financial officer now directly owns 41,791 shares in the company, valued at $1,127,521.18. The sale was disclosed in a document filed with the SEC, which is available at this link.

William Richard White also recently made the following trade(s):

• On Tuesday, July 16th, William Richard White sold 34,811 shares of Akero Therapeutics stock. The shares were sold at an average price of $28.04, for a total transaction of $976,100.44.
• On Tuesday, June 11th, William Richard White sold 2,831 shares of Akero Therapeutics stock. The stock was sold at an average price of $22.64, for a total transaction of $64,093.84.

Akero Therapeutics Trading Down 0.7 %

NASDAQ AKRO opened at $28.12 on Friday. The stock has a market cap of $1.94 billion, a P/E ratio of -8.79 and a beta of -0.28. Akero Therapeutics, Inc. has a fifty-two week low of $11.25 and a fifty-two week high of $53.77. The stock has a 50 day simple moving average of $22.98 and a two-hundred day simple moving average of $22.99. The company has a debt-to-equity ratio of 0.04, a quick ratio of 30.12 and a current ratio of 30.12.

Akero Therapeutics (NASDAQ:AKRO) last announced its earnings results on Friday, May 10th. The company reported ($0.90) EPS for the quarter, meeting analysts’ consensus estimates of ($0.90). On average, analysts forecast that Akero Therapeutics, Inc. will post -3.82 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on AKRO shares. Evercore ISI reduced their price objective on Akero Therapeutics from $50.00 to $38.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 15th. Bank of America initiated coverage on Akero Therapeutics in a research report on Monday, April 22nd. They set a “neutral” rating and a $30.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Akero Therapeutics in a research report on Thursday, June 20th. HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Akero Therapeutics in a research note on Tuesday, June 11th. Finally, Wolfe Research started coverage on shares of Akero Therapeutics in a research note on Tuesday, June 11th. They issued an “outperform” rating on the stock. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $41.13.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in AKRO. RTW Investments LP purchased a new position in shares of Akero Therapeutics during the fourth quarter valued at about $83,891,000. Wellington Management Group LLP boosted its position in Akero Therapeutics by 247.7% during the 4th quarter. Wellington Management Group LLP now owns 2,881,989 shares of the company’s stock valued at $67,294,000 after acquiring an additional 2,053,028 shares in the last quarter. Janus Henderson Group PLC boosted its position in Akero Therapeutics by 42.2% during the 1st quarter. Janus Henderson Group PLC now owns 6,121,970 shares of the company’s stock valued at $154,589,000 after acquiring an additional 1,815,569 shares in the last quarter. Redmile Group LLC grew its holdings in shares of Akero Therapeutics by 67.5% during the 1st quarter. Redmile Group LLC now owns 1,858,702 shares of the company’s stock worth $46,951,000 after acquiring an additional 749,226 shares during the period. Finally, Vanguard Group Inc. raised its position in shares of Akero Therapeutics by 19.0% in the 1st quarter. Vanguard Group Inc. now owns 3,669,923 shares of the company’s stock worth $92,702,000 after acquiring an additional 584,875 shares in the last quarter.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.